Hepalink's FOYA-winning syringe plant inspects 24,000 units an hour

Hepalink needed to put 330 million prefilled syringes a year onto a plot of Shenzhen land that had no room to spread. In an April 21, 2026 press release, the company said the Pingshan site faced extreme land scarcity, so its engineers built the plant upward and sank a 24-meter-high automated warehouse into its core. The result won the Innovation (Novel Technology) category of the 2026 ISPE Facility of the Year Awards.

The International Society for Pharmaceutical Engineering (ISPE) announced the category winners on April 20, 2026, at its Europe Annual Conference in Copenhagen, BioProcess International reported the same day. In October 2026, CaiXue Wei, Vice President of Manufacturing and Operations, Global Industrial Affairs at Hepalink, joined host Bob Chew on ISPE's podcast, Shaping the Future of Pharma, to explain how the plant came together. That same month, in an October 7, 2026 press release from CPHI Milan, Hepalink said the project was the only Chinese winner on the 2026 roster.

In the written transcript ISPE posted alongside the episode, Wei answered that the plant treats capacity, sterility assurance, quality control and digital coordination as one integrated system. Within limited land, he said, automated warehousing, isolator filling, AI inspection, 5G and digital systems together improve space use, efficiency and supply stability. FOYA, in his words, recognized practical, system-level innovation built around real manufacturing needs rather than any single technology.

For a fill-finish operations lead planning a sterile injectables build, the Pingshan figures are a benchmark set: the latency, the inspection rate, the warehouse height and the space gain. Each one has a mechanism behind it. Some of those mechanisms are easier to copy than others.

Shenzhen's land shortage sent the warehouse 24 meters into the air

Hepalink's 24-meter automated warehouse raised space utilization 52 percent over a traditional layout, the company said in its April 2026 release. A stereoscopic warehouse, the term Hepalink uses, is automated high-bay racking: materials sit in tall steel shelving and machines, not forklift drivers, retrieve each pallet or tote. Embedding that tower in the middle of the building put storage beside production instead of at the far end of a site.

The plant covers 297,715 square feet of floor area, was completed on February 4, 2025, and holds EU GMP certification, according to the same release. EU GMP is the European Union's good manufacturing practice standard, the inspection regime a plant must pass before its medicines can be supplied to the EU market. ISPE's own write-up of the project, posted on its site in September 2026, describes the location as one of China's most land-constrained urban environments and the vertical layout as a rethink of how a pharmaceutical plant is usually arranged.

A vertical plant changes the logistics question before it changes anything else. When storage is stacked above the line instead of strung along a long horizontal flow, every move of material becomes a machine move, and a lift or a cart has to be timed against the filling line it feeds. That is the link between the building's shape and the automation that follows.

Enoxaparin's viscosity seizes pumps before it troubles a patient

The force needed to push a viscous liquid through a syringe needle rises in direct proportion to viscosity and climbs steeply as the needle bore narrows. Michael Adler, a Roche formulation scientist, laid out that relationship in a February 2012 American Pharmaceutical Review article using the Hagen-Poiseuille equation, which ties flow rate, viscosity, needle length and needle inner diameter to the travel force on the plunger. Of those variables, Adler wrote, the formulation scientist can change only viscosity; the syringe fixes everything else, and no generally accepted limit exists for injection force or injection time.

On a filling line the same property shows up differently. Hepalink's April 2026 release lists pump seizing on high-viscosity drugs and glass breakage during high-speed inspection as the industry problems the Pingshan project solved. Enoxaparin sodium, the anticoagulant the plant fills, is the high-viscosity product in question, and a dosing pump that stalls under a viscous load stops the line until it is cleared.

Wei's written answer widened the question. The main challenge, he said in the transcript ISPE posted, was building a plant that could meet large-scale capacity, international quality standards and sterility assurance requirements at the same time. The team combined vertical design, automated storage, isolator filling, AGV transfer, AI inspection and 5G coordination to attack space, capacity, quality and efficiency together.

On the patient's side of the problem, the established fix is still the syringe itself. A December 2025 study in the European Journal of Pharmaceutics and Biopharmaceutics (EJPB), published by Elsevier, found that moving from a 29-gauge to a 27-gauge needle cut glide force by 59 percent, from 32 newtons to 13, when injecting 1 milliliter of a 20-centipoise fluid over 10 seconds. Centipoise is the unit of viscosity, and glide force is the push a user applies to the plunger; the same study ties silicone oil coating, barrel diameter and plunger stopper contact length to that force. That work happens at the device design bench, before a filling line is involved.

Those two findings describe different ends of the product's life. Needle gauge governs what the patient feels, while pumps, nests and inspection cameras govern whether the syringes get filled and checked at volume. Hepalink's technologies live on the second end, and that is the half its FOYA entry describes.

A sunken 5G edge network holds latency under 10 milliseconds

Hepalink's release puts network latency on the plant's 5G multi-access edge computing architecture at less than 10 milliseconds. Multi-access edge computing, or MEC, means the servers that process plant data sit inside the facility beside the radio network, so a camera frame or an AGV position report never leaves the site to be processed. Hepalink calls the setup fully sunken, and its October 2026 release says this keeps data processing close to the production areas; ISPE's September 2026 write-up adds that the loop stays closed locally, which keeps the plant's data on the plant's own servers.

In the transcript ISPE posted, Wei said the localized 5G-MEC layer carries AGV dispatching, AI image transmission, equipment monitoring and data collection for the MES and SCADA systems. A manufacturing execution system (MES) is the software that records each step of a batch, and SCADA (supervisory control and data acquisition) is the layer that reads and adjusts equipment. The image traffic is where latency bites: arithmetic on Hepalink's 24,000 units an hour puts nearly seven syringes a second in front of the inspection cameras, so each frame has to reach the edge servers and come back with a verdict inside that window.

The same ISPE post describes a 5G electronic fence: AI vision systems watching work areas in real time for unsafe behavior, plus millisecond-level collision avoidance for the AGVs. It also reports an 18 percent reduction in unit energy consumption and estimated annual electricity savings of about RMB 4.09 million, roughly US$560,000, from thermal energy storage and energy management tied into the same network.

How rare is a 5G factory? Hepalink's release calls Pingshan a lighthouse project, its term for a reference site, and notes its listing in the Chinese Ministry of Industry and Information Technology's 2025 5G Factory Directory, which Shenzhen Daily describes as recognition for advanced digital and intelligent systems integration. The same Shenzhen Daily item, published May 9, 2026 and republished by the Pingshan District government, counts three 5G-enabled factories in the district alone, Hepalink among them, beside 30 advanced smart factories. A 5G floor in a Shenzhen factory is an established pattern; what the FOYA category rewarded, by ISPE's own description, is the application of that network to AGV transfer, inspection and environmental monitoring inside a sterile plant.

AGVs carry material into Grade A isolators without a human hand

Hepalink says the Pingshan line moves material from warehouse to Grade A isolators with no human handling, and it calls the design an industry first. An automated guided vehicle (AGV) is a driverless cart that follows a programmed route; a Grade A isolator is a sealed enclosure at the highest EU GMP cleanliness grade, where open product is filled and no operator reaches in. Between them, by the April 2026 release's description, sits a vaporized hydrogen peroxide (VHP) transfer chamber, a pass-through that fogs incoming surfaces with hydrogen peroxide vapor to decontaminate them before they enter the isolator. The chain works as a sequence of handoffs: the AGV docks at the chamber, the chamber runs its cycle, and the load passes into the isolator, with the 5G network carrying the dispatch and docking signals that time each step.

Wei answered, in the transcript on ISPE's site, that the project put AGVs and conveyor lines for items and totes into material transfer, so operators are released from frequent manual handling and instead confirm schedules, hand off between process steps and deal with exceptions. That split, he said, improves logistics efficiency and production coordination while cutting unnecessary manual contact. ISPE's write-up puts the logistics network's delivery stability at 99.99 percent.

Sterility is where the design pays off. Hepalink's April 2026 release reports a 100 percent success rate in the plant's first media-fill simulation, which it credits directly to the zero-touch design. A media fill runs the filling line with microbial growth medium instead of drug and then incubates the units; any growth means the process let contamination in, and every human reach toward open product is one of the ways it gets in. The detail a sterile operations lead can check on a plant tour is where a person still enters the flow, which by Wei's description is scheduling, handover and exceptions, and nowhere between the warehouse and the isolator.

Deep-learning inspection reads 24,000 syringes an hour

Hepalink says its deep-learning inspection machine checks 24,000 syringes an hour without glass touching glass. The April 2026 release describes an all-in-one nest removal and inspection machine; a nest is the plastic tray that holds filled syringes inside a sealed tub, and lifting syringes out of it for inspection is where glass used to break at speed. Combining removal and inspection in one machine takes out the transfer step where syringes knocked together. Hepalink reports 100 percent defect detection on the system.

The AI here is machine vision, by Hepalink's description. Deep learning in this setting means software trained on large sets of images of good and defective units, which then classifies each syringe as it passes a camera; neither Hepalink release describes predictive control of the filling process itself. ISPE's September 2026 post says the inspection runs at efficiencies far beyond manual methods and that one operator can oversee multiple machines.

Hepalink has not published how it validated the deep-learning classifier for defect decisions on a GMP line, so a quality lead cannot yet read Pingshan as a template for AI validation under any regulator's guidance. What the company has put on the record is the throughput figure and the mechanical change that made it possible: no glass-to-glass contact during nest removal.

A digital twin lets Pingshan and Nanshan share recipes

Hepalink's April 2026 release describes a digital twin collaborative model linking the Pingshan and Nanshan sites, built for rapid transfer of technical resources and production recipes. A digital twin, in the company's October 2026 description, is a synchronously mapped digital copy of the physical plant that allows real-time perception, simulation and continuous optimization of the process. A recipe, in this context, is the full set of parameters and steps that define how a batch is made, so a shared twin means a recipe proven at one site can be run against the model of the other before it is run on the floor.

The reason that matters is the product's reach. Hepalink said in its April release that enoxaparin sodium injection was approved in 78 countries and regions and sold in more than 50; by October 2026 the company put approvals at 81 countries and regions. The company describes nearly three decades in heparin and a vertically integrated chain running from raw material through active pharmaceutical ingredient (API), the drug substance itself, to finished formulation and global commercialization.

Techdow, Hepalink's wholly owned subsidiary, has carried the enoxaparin business since 2004, and its Inhixa became the first enoxaparin sodium biosimilar approved by the European Medicines Agency in 2016, Hepalink said in the October 2026 release. A biosimilar is a follow-on version of a biological medicine approved by showing it matches the original. For a supply chain planner, the Nanshan link is the resilience argument: Hepalink's own claim is that a shared digital model and the plant's added capacity strengthen stable supply across those markets.

What FOYA judges weigh in a Novel Technology entry

Scott Billman, a FOYA judge and Senior Vice President of Global Engineering, Technology, and Facilities at Solventum, told The Medicine Maker in an October 2025 interview that submissions open each August and that an ISPE committee first checks every entry against minimum criteria, including that the facility is actually producing the therapy it was built for and that construction met high safety standards. Only then does a panel of senior project leaders judge the field. Billman listed Novel Technology as one of five Innovation subcategories, beside Facility of the Future, Process Innovation, Process Intelligence and Equipment Innovation, and said the categories are revisited every year; ISPE's own site describes the Novel Technology award as recognizing innovative application of manufacturing technologies, facility design and engineering solutions.

Pharmaceutical Technology, in an April 22, 2026 report, said the program dates from 2005 and that judges consider how facilities are designed, delivered and operated, with this year's panel weighing modular and digital manufacturing, sustainability-focused infrastructure, accelerated execution and integrated quality and supply strategies. It cited Parag Sane of Amgen, the judging chair, calling the winners new benchmarks for regulated manufacturing. ISPE does not publish a side-by-side scoring of past Novel Technology winners, so Pingshan's margin over earlier entries in the category cannot be measured.

ISPE will name the overall 2026 winner at its Annual Meeting & Expo in Washington, DC, in October, BioProcess International reported. The measure Wei himself set is replication: in ISPE's September 2026 post he described the plant as a stable and replicable model for large-scale, high-standard sterile prefilled syringe manufacturing. Whether a second Hepalink line, or another company's, reproduces the sub-10 millisecond network, the zero-touch isolator feed and the 24,000-unit inspection rate is the signal Wei points to.